Luzira rarely appears at the centre of major industrial turning points.
The Kampala neighbourhood is better known for its prison, fish market and warehouses near Lake Victoria. Its air carries the smell of diesel and lake water.
Yet inside one of its factories, Quality Chemical Industries Limited is deepening a 20-year bet on local medicine production.
In May 2026, the company launched Sikurea, its brand name for hydroxyurea. The drug is widely used to manage sickle cell disease.
The launch marks a new step for a company built around producing medicine in Africa, for Africa.
Strongest results in 20 years
Quality Chemical was founded in 2005 as a joint venture between Ugandan investors and Cipla, the Indian generics manufacturer.
The company was created to manufacture World Health Organisation-approved generic medicines locally.
Its latest financial results suggest the model has gained strength.
For the financial year ended March 2026, Quality Chemical posted its strongest performance in 20 years.
Revenue rose by 8.7 percent to Shs290.5 billion.
For every Shs1,000 in sales, about Shs194 remained as net profit after expenses, interest and tax.
That points to a strong net profit margin.
The company also retained more money from each sale after production costs.
For every Shs100 it earned, it kept Shs46.7 after production costs, up from Shs40.6 the previous year.
The improvement reflected stronger production efficiency and lower waste on raw materials.
Total profit rose by more than a third to Shs56.4 billion.
The results included a Shs4.4 billion windfall from money the company had previously given up on collecting from the Zambian government.
Even without that recovery, profit still grew by about a quarter.
Quality Chemical also more than doubled cash generated from daily operations.
Operating cash flow rose to Shs67.5 billion from Shs30.3 billion a year earlier.
Expeditto Gitta, an equities consultant who tracks the Uganda Securities Exchange, said that matters because the company is preparing a major expansion at its Luzira site.
Stronger internal cash generation means the company may need to borrow less to fund the project.
Dividend returns draw attention
Quality Chemical’s dividend has also drawn investor interest.
At Shs140 per share, based on the company’s market value as of June 2, new investors would receive a dividend yield of 11.9 percent.
Older investors would receive a yield of 27.6 percent.
Cash used in financing activities rose to Shs59.3 billion from Shs42.5 billion the previous year.
The company attributed the increase “mainly to the higher dividend distribution during the year”.
Sikurea targets sickle cell treatment gap
Hydroxyurea has been available in wealthy countries since the 1990s.
In Africa, however, access has remained limited.
The Africa Centres for Disease Control and Prevention says about 240,000 children are born with sickle cell disease on the continent every year.
That represents 80 percent of the global total.
Until now, hydroxyurea had to be imported into the region. This made supply expensive, unreliable and inaccessible for many patients.
No company in sub-Saharan Africa had manufactured the drug locally.
Quality Chemical has now moved into that space with Sikurea.
Permanent Secretary Diana Atwine said the Ministry of Health is committed to listing Sikurea on the national essential medicines catalogue.
That listing would trigger annual procurement and distribution through the public health system.
The launch also comes after Parliament passed a resolution on sickle cell funding.
Seven days before the May 20 launch, 50 African Union member states validated a Continental Framework for Sickle Cell Disease.
Its pillars include local medicine production and continental pooled procurement.
Quality Chemical had already delivered one of the key elements in that framework.
The company currently holds regulatory approvals in 31 African markets.
Building a WHO-prequalified plant requires years of regulatory work and heavy capital investment.
Quality Chemical has spent two decades building both.
Second Luzira plant under development
The company is now building a second plant next to its existing Luzira facility.
It says the new factory will “support entry into new therapeutic areas such as tuberculosis and sickle cell anaemia, and introduce an injectable line consistent with evolving patient treatment preferences.”
In May 2025, Quality Chemical secured a $36 million loan from Stanbic Bank.
It was the largest loan in the company’s history.
The facility carries interest at the Secured Overnight Financing Rate plus 3.75 percent.
It matures after 84 months and includes a 24-month grace period before principal repayments begin.
By March 2026, the company had not drawn any money from the facility.
The Shs18 billion spent on construction by that time came entirely from operating cash flow.
Once commissioned within 24 months, the new plant is expected to raise tablet production capacity from 1.4 billion to 2.4 billion units.
That represents a 71 percent expansion.
The plant will target tuberculosis medicines, a category where the company says Africa currently has no manufacturer.
It will also support injectable formulations, including Lenacapavir, a new HIV prevention drug that requires two injections a year.
Quality Chemical says it is “currently operating near its manufacturing capacity”.
Market valuation remains discounted
Quality Chemical shares traded at Shs143 on June 2.
That gave the company a market capitalisation of about Shs522 billion.
For the 2026 financial year, earnings per share stood at Shs15.45.
At that price, the stock traded at 9.3 times earnings.
Cipla, its founding partner and closest comparable, trades at about 23 times earnings.
The global pharmaceutical average is around 22 times.
The discount partly reflects the company’s ownership structure.
The top 10 shareholders control 98.24 percent of Quality Chemical.
That leaves a free float of only 1.76 percent, or fewer than 64 million shares.
Average daily trading volume remains below 5,000 shares.
The stock gained 23.3 percent from January 2026, according to Uganda Securities Exchange data.
It also rose 13 percent in the four weeks around the Sikurea launch.
That was the strongest run on the exchange during that period.
Investor questions remain
Quality Chemical still faces several risks.
The board has cited pricing pressure on its core antiretroviral products.
It also highlighted the long-term incentive scheme, which carried an Shs11 billion provision in the 2026 financial year.
That was up from Shs2.3 billion and is expected to crystallise into cash.
The company also has Shs11.5 billion still outstanding from Medpro Pharmaceutica.
In addition, the 24-month construction timeline carries execution risk in a frontier market.
Still, the broader picture remains clear.
Quality Chemical is profitable and cash-generative.
It has posted three consecutive years of earnings growth.
Its gross margin is approaching 47 percent.
It has launched a new drug that could enter recurring government procurement.
It is also building a second plant targeting two medicine categories where Africa has no manufacturer.
Yet the market continues to value the company at a discount to comparable pharmaceutical firms.
